BioCentury | Jan 27, 2021
Finance

Pontifax raises largest-ever fund at $404M

Building on a string of successful exits with its sixth and largest fund, Pontifax Venture Capital will now have a larger reserve of capital to maintain its ownership stakes in portfolio companies into the growth...
BioCentury | Jan 27, 2021
Product Development

KSQ sets sights on the clinic as new CEO steps in

KSQ is setting a path to advance targeted oncology and immuno-oncology programs emerging from its CRISPR-based target discovery platform with the appointment of Qasim Rizvi as its new CEO and a recent deal with Takeda. Under...
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is headed into the clinic with two targeted programs for non-small cell lung...
BioCentury | Jan 27, 2021
Product Development

Leaving cancer behind, Agios preps submission after latest readout in rare anemia

With its oncology business in the rear view mirror, Agios is readying its first non-cancer candidate for a regulatory submission with more data in a rare anemia. After the bell Tuesday, Agios Pharmaceuticals Inc. (NASDAQ:AGIO)...
BioCentury | Jan 27, 2021
Deals

Jan. 26 Quick Takes: Sanofi to manufacture more than 100M doses of Comirnaty; plus Qiming, Nirogy, Takeda-Evozyne and Vir

Under a new deal with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), Sanofi (Euronext:SAN; NASDAQ:SNY) will produce more than 100 million doses of COVID-19 vaccine Cormirnaty in Europe in 2021. Sanofi spokesperson Nicolas Kressmann said...
BioCentury | Jan 26, 2021
Product Development

Where companies are testing COVID-19 therapies and vaccines: Data Byte

The U.S. remains the hotbed of COVID-19 therapeutics testing, but China is conducting almost as many vaccine trials.  As of Jan. 25, there were over 700 active COVID trials listed in public registries that had...
BioCentury | Jan 26, 2021
Politics, Policy & Law

EU transparency scheme raises concerns over potential COVID-19 vaccine export restrictions

Controversy over a reduction in projected shipments of AstraZeneca’s COVID-19 vaccine to the EU have prompted the European bloc to propose a scheme that would require vaccine manufacturers to notify the EU government head of...
BioCentury | Jan 26, 2021
Emerging Company Profile

Resolution: Fighting fibrosis with macrophages

Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.  The Syncona-backed company launched...
BioCentury | Jan 26, 2021
Politics, Policy & Law

Warp Speed reflections, master protocols & Biden’s COVID plan: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the successes and limitations of Operation Warp Speed, proposals for streamlining master protocol trials and highlights for industry from the Biden administration’s COVID-19...
Items per page:
1 - 10 of 212389